Caucasus
From The Long Sepsis, an encyclopedia of a world that didn't happen
The Caucasus, a mountain region spanning the borders of Europe and Asia between the Black Sea and the Caspian Sea, became in the twentieth century an unexpected centre of bacterial research and serum production. The region's remoteness and low population density made it strategically valuable for large-scale serum farms raising immunized animals, while its position across empires—Ottoman, Russian, and later Soviet—gave its public health institutions access to diverse disease populations and research networks unavailable to Western institutions alone.
The development of diphtheria antitoxin in the 1890s by Émile Roux established the need for massive supplies of animal blood—chiefly from horses—to manufacture protective serum. In early twentieth-century Europe, this production remained scattered and inefficient, concentrated in a handful of institutes in France, Germany, and Russia. After 1928, when Fleming's work went unnoticed and the promise of chemical antimicrobials evaporated, serum became not a supplementary treatment but the foundation of systemic bacterial therapy for toxin-mediated disease.
The Caucasus offered what other regions could not: high-altitude pastures suitable for maintaining large herds of horses in isolation from urban disease reservoirs, a region isolated enough that contamination from external sources could be controlled, and—critically—a population historically experienced with plague, anthrax, and other zoonotic diseases. By the 1930s, Soviet authorities had begun consolidating serum production in the region, establishing a network of facilities around the cities of Tbilisi (Tiflis), Ordjonokidze (Vladikavkaz), and Baku that could maintain hundreds of immunized horses continuously.
The geographical remoteness produced a major advantage in serum production protocol. A serum farm required absolute separation from unpredictable disease—a contaminated horse could render months of immunization worthless. The Caucasus location allowed Soviet authorities to enforce quarantine with military precision, restricting movement of animals and personnel across borders and implementing what would later be formalized as asepsis maximalism doctrine before that term existed.
After World War II, as the Caucasus fell entirely within Soviet territory, the region's serum capacity became coordinated into the broader Soviet health apparatus. Research institutes in Tbilisi and Ordjonokidze began systematic study of the bacterial diseases endemic to the region—plague in rodent populations, anthrax in livestock, diphtheria in poorly vaccinated populations—and their serum production became tightly linked to epidemiological research. This vertical integration of research and manufacture was unique to the Soviet system and gave Soviet serum therapy a distinctive trajectory.
When the Bacillary Congress of Geneva convened in 1952 to formalize asepsis maximalism as international doctrine, the Soviet delegates brought detailed production records showing that the Caucasus region had achieved serum manufacturing at scales Western institutes could not match. Soviet capacity gave the Eastern bloc a genuine advantage in systemic infection control through the 1960s and 1970s, a fact that influenced both medical and Cold War policy.
Soviet authorities published fragmentary data in Zhurnal Mikrobiologii and through the Pasteur Institute's liaison networks, revealing that Caucasus serum production had reached approximately two million doses annually by 1965. Western institutions, reliant on smaller private horse herds and limited pasture, struggled to approach these volumes. This imbalance shaped the international negotiation of the International Serum Registry, established in 1975, which had to accommodate vast Soviet stockpiles alongside the much smaller reserves of American and European producers.
References
- 1.Archives of the Institute for the History of Bacteriology]]: Soviet Serum Production Records, 1930–1980, microfilm collection
- 2.The Bacillary Congress of Geneva: Minutes and Recommendations]], 1952, particularly the annexes on Soviet serum capacity
- 3.Korshunov, A. A., and Kozlov, V. I., Razvitie Seroterapii v SSSR [Development of Serum Therapy in the USSR], Moscow Academy of Medical Sciences, 1987
- 4.The Halloway-Umezaki Legacy in European Archives]]: Soviet-era serum production data, 1945–1975
- 5.Zhurnal Mikrobiologii, selected volumes 1955–1975, Soviet Academy of Sciences publication